Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) presented clinical data at the American College of Cardiology's Annual Scientific Session supporting its cardiovascular drug portfolio, according to a company statement.

The data included analyses of vutrisiran, marketed as AMVUTTRA, for treating transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Studies showed the drug improved health-related quality of life measures and demonstrated efficacy across disease severity levels, including patients with advanced disease and diastolic dysfunction.

A quality of life analysis using the Kansas City Cardiomyopathy Questionnaire showed vutrisiran improved physical limitations and quality of life compared to placebo. The treatment effect was comparable to differences seen in patients 11 years apart in age.

In patients with advanced disease, vutrisiran reduced the risk of death and cardiovascular events by 40% in the overall population and 46% in patients receiving monotherapy compared to placebo during the study period.

Real-world data showed 93.8% of patients maintained adherence to vutrisiran's quarterly dosing schedule over an average follow-up of 613.8 days.

The company also presented pooled Phase 2 safety data for zilebesiran, an investigational treatment for hypertension. The analysis demonstrated what the company described as an acceptable safety profile across different patient populations, including those receiving the drug with standard blood pressure medications.

Zilebesiran targets angiotensinogen and is designed to provide blood pressure control with twice-yearly dosing. The drug is being evaluated in a Phase 3 cardiovascular outcomes trial called ZENITH, which began in September 2025.

Vutrisiran is approved by the U.S. Food and Drug Administration for treating ATTR-CM and hereditary transthyretin-mediated amyloidosis polyneuropathy in adults. Zilebesiran remains investigational and is being co-developed with Roche.